Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review With Meta-analysis
Authors' conclusion
This meta-analysis highlights the importance of tailoring treatment strategies based on TED duration, emphasizing early interventions to maximize benefits. The findings guide clinicians in selecting optimal treatments and underscore the need for further research to refine evidence-based approaches, ultimately enhancing patient outcomes and quality of life.
Study context
- Population
- Patients with thyroid eye disease (TED)26 studies
- Comparison
- Treatments initiated in initial phase vs subacute/chronic phase
- Outcome
- Inflammatory markers and severity endpoints (clinical activity score, proptosis, diplopia)
Methodological detailsPRISMA guidelines, stratified by disease duration
- PRISMA guidelines
- Stratified by disease duration
Pooled result
As reported in the abstract
Clinical activity score, proptosis and diplopia
- Initial phase: corticosteroids and teprotumumab showed significant improvements in clinical activity score, proptosis and diplopia
- Subacute/chronic phase: efficacy of methylprednisolone and teprotumumab reduced
- "Critical window" effect: diminished efficacy after 6 months of TED duration
Original publication
Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review With Meta-analysis. J Clin Endocrinol Metab. Published 30 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →